{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-042331","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.156001+00:00","generated_at":"2026-05-24T10:44:52.316402+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Invivyd Q4 2024 PEMGARDA revenue $13.8M (+48% QoQ); FY2024 net loss $169.9M; FDA rejects EUA expansion for treatment","bullets":["Q4 2024 net product revenue $13.8M, up 48% from Q3 $9.3M; full-year 2024 net product revenue $25.4M.","Cash and cash equivalents $69.3M at Dec 31, 2024; targeting near-term profitability by end of 1H 2025 with existing cash and expected revenue growth.","FDA declined request to expand PEMGARDA EUA for treatment of mild-to-moderate COVID-19 in immunocompromised; Invivyd submitted reconsideration request.","Phase 1 data for VYD2311 shows average 17-fold greater neutralization potency than pemivibart; commercial mfg substantially completed.","Net loss for 2024 $169.9M ($1.43 per share) vs $198.6M ($1.81 per share) in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-042331","json":"https://secwatch.observer/filing/0000950170-25-042331.json","markdown":"https://secwatch.observer/filing/0000950170-25-042331.md","text":"https://secwatch.observer/filing/0000950170-25-042331.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025042331/0000950170-25-042331-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025042331/ivvd-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:44:52.316402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}